Amyloidosis News - April 2021

The HELIOS-A study of vutrisiran in patients with hereditary transthyretin amyloidosis met the primary and all secondary end points. Read More ›

Diagnosis of this disease is often missed and still underdiagnosed, despite recent diagnostic improvements and the use of scintigraphy. Read More ›

The inclusion of patients who also have cardiac amyloidosis in clinical trials evaluating treatments for heart failure with preserved ejection fraction may help explain the underperformance of drugs that are effective in other forms of heart failure. Read More ›

] V122I TTR variant carrier status is associated with specific subclinical cardiac abnormalities in middle age. Read More ›

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.